Axsome Therapeutics’ Auvelity won FDA approval for Alzheimer’s disease agitation, giving the company access to a large commercial market tied to a population of patients with agitation symptoms. The approval positions Auvelity as a label expansion for a condition that affects up to three-quarters of patients with Alzheimer’s. The decision also sharpens competitive dynamics among neurology treatments targeting behavioral symptoms in Alzheimer’s, where the presence or absence of boxed warnings can influence formulary adoption. For providers and payers, Auvelity’s new indication changes how clinicians may build treatment algorithms for agitation. In a related business move, Esperion is reported to go private in a $1.1 billion deal, underscoring continued consolidation momentum in cardiometabolic drug development. Overall, today’s headlines combine regulatory progress in neuropsychiatry with corporate restructuring, both of which can redirect near-term revenue expectations across adjacent therapeutic areas.